Science and know-how firm Danaher Company (DHR), headquartered in Washington, D.C., designs, manufactures, and markets revolutionary services and products within the fields of life sciences, diagnostics, and biotechnology. The corporate operates via three broad segments: Biotechnology, Life Sciences, and Diagnostics.
With a market capitalization of $147.31 billion, Danaher’s choices are utilized in analysis labs, hospitals, and industrial settings to advance scientific discovery, enhance affected person care, and guarantee water high quality and meals security. Shares of this medical know-how firm have declined by 22.2% over the previous 52 weeks, as the corporate experiences a slowdown in its efficiency.
For comparability, the broader S&P 500 Index ($SPX) has gained 19% over the identical interval. This 12 months, Danaher’s inventory value has declined by 8.9% year-to-date (YTD), whereas the S&P 500 index has elevated by virtually 10%.
Taking a better look, Danaher’s shares have additionally been underperforming the sector-specific Robo World Healthcare Know-how and Innovation ETF (HTEC), which has gained 5.2% over the previous 52 weeks and 4.7% YTD.
For the fiscal 12 months 2024, Danaher’s topline declined marginally year-over-year (YOY). Whereas the corporate’s weak value motion has coincided with an annual topline slowdown, its latest quarterly financials got here in higher than anticipated, sparking a 4.2% surge in its share on Jul. 23. For the second quarter of fiscal 2025, its gross sales elevated by 3.4% YOY to $5.94 billion, which was higher than the $5.84 billion that Wall Avenue analysts had been anticipating.
On the coronary heart of this development was the Danaher Enterprise System, together with positive aspects in its bioprocessing enterprise. Together with its newest earnings reveal, Danaher additionally introduced a notable government shakeup, with a brand new CFO anticipated to take over subsequent 12 months and a brand new Normal Counsel already appointed.
For the fiscal 12 months 2025, ending in December 2025, Wall Avenue analysts anticipate a modest development in Danaher’s backside line, forecasting a 3.9% YOY development in its EPS to $7.77 on a diluted foundation. The corporate has a blended historical past of surpassing consensus estimates, topping them in three of the trailing 4 quarters and lacking them on one event.